Neuraxis, INC 10-Q

ITEM 1. FINANCIAL STATEMENTS NeurAxis, Inc. Condensed Balance Sheets March 31, 2026 December 31, 2025 (Unaudited) Assets Current Assets: Cash and cash equivalents $ 7,078,659 $ 4,965,072 Accounts receivable, net of credit losses of $ 7,220 and $ 7,326 as of March 31, 2026 and December 31, 2025, respectively 385,009 195,703 Inventories, net of reserves of $ 28,048 and $ 34,524 as of March 31, 2026 and December 31, 2025, respectively 238,282 257,132 Prepaids and other current assets 441,075 315,283 Total current assets 8,143,025 5,733,190 Property and Equipment, at Cost 382,465 382,465 Less - accumulated depreciation ( 314,935 ) ( 306,901 ) Property and equipment, net 67,530 75,564 Other Assets: Operating lease right of use asset, net 245,350 261,565 Intangible assets, net 266,494 274,778 Other non-current assets 23,307 58,939 Total Assets $ 8,745,706 $ 6,404,036 Liabilities Current Liabilities: Accounts payable $ 305,296 $ 139,365 Accrued expenses 2,261,447 2,393,229 Current portion of operating lease payable 68,789 65,752 Notes payable 100,735 148,293 Customer deposits 29,585 28,660 Warrant liabilities 48,306 16,800 Total current liabilities 2,814,158 2,792,099 Non-Current Liabilities: Operating lease payable, net of current portion 183,998 202,566 Other non-current liabilities — 9,999 Total liabilities 2,998,156 3,004,664 Commitments and contingencies (see note 15) Stockholders’ Equity Convertible Series B Preferred stock, $ 0.001 par value; 5,000,000 shares authorized, 3,796,907 shares issued and outstanding as of March 31, 2026 and December 31, 2025 3,797 3,797 Common stock, $ 0.001 par value; 100,000,000 shares authorized; 11,450,045 and 10,652,812 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively 11,450 10,653 Additional paid in capital 72,093,902 67,985,089 Accumulated deficit ( 66,361,599 ) ( 64,600,167 ) Total stockholders’ equity 5,747,550 3,399,372 Total Liabilities and Stockholders’ Equity $ 8,745,706 $ 6,404,036 The accompanying notes are an integral part of these unaudited condensed financial statements 3 NeurAxis, Inc. Condensed Statements of Operations (Unaudited) 2026 2025 For the Three Months Ended March 31, 2026 2025 Net Sales $ 1,607,883 $ 895,655 Cost of Goods Sold 218,366 139,475 Gross Profit 1,389,517 756,180 Selling Expenses 824,336 500,119 Research and Development 99,567 117,867 General and Administrative 2,206,293 2,433,292 Operating Loss ( 1,740,679 ) ( 2,295,098 ) Other Income (Expense): Interest expense ( 26,189 ) ( 2,237 ) Change in fair value of warrant liability ( 31,506 ) 1,831 Other income 36,942 16,820 Total other (expense) income, net ( 20,753 ) 16,414 Net Loss ( 1,761,432 ) ( 2,278,684 ) Preferred stock dividends ( 189,399 ) ( 213,543 ) Net Loss Available to Common Stockholders $ ( 1,950,831 ) $ ( 2,492,227 ) Per-Share Data Basic and diluted loss per share $ ( 0.18 ) $ ( 0.33 ) Weighted Average Common Shares Outstanding Basic and diluted 10,948,121 7,463,578 The accompanying notes are an integral part of these unaudited condensed financial statements 4 NeurAxis, Inc. Condensed Statements of Stockholders’ Equity (Unaudited) Shares Amount Shares Amount Capital Deficit Equity Convertible Series B Preferred Stock Common Stock Additional Paid In Accumulated Stockholder’s Shares Amount Shares Amount Capital Deficit Equity Balances at January 1, 2025 4,280,939 $ 4,281 6,990,227 $ 6,990 $ 58,856,089 $ ( 56,799,612 ) $ 2,067,748 Warrants exercised - - 186,166 186 ( 186 ) - - Common stock issued from agreements - - 39,471 40 112,453 - 112,493 Stock-based compensation - - - - 105,811 - 105,811 Additional paid in capital from restricted stock units - - - - 251,111 - 251,111 Net loss - - - - - ( 2,278,684 ) ( 2,278,684 ) Balances at March 31, 2025 4,280,939 $ 4,281 7,215,864 $ 7,216 $ 59,325,278 $ ( 59,078,296 ) $ 258,479 Balances at January 1, 2026 3,796,907 $ 3,797 10,652,812 $ 10,653 $ 67,985,089 $ ( 64,600,167 ) $ 3,399,372 Balance 3,796,907 $ 3,797 10,652,812 $ 10,653 $ 67,985,089 $ ( 64,600,167 ) 3,399,372 Warrants exercised - - 213,040 213 506,822 - 507,035 Common stock issued from agreements - - 86,392 86 399,909 - 399,995 Issuance of common stock pursuant to shelf registration statement - - 495,456 495 2,989,866 - 2,990,361 Offering costs - - - - ( 110,431 ) - ( 110,431 ) Common stock issued under the 2022 Omnibus Securities and Incentive Plan - - 2,345 3 ( 6,787 ) - ( 6,784 ) Stock-based compensation - - - - 329,434 - 329,434 Net loss - - - - - ( 1,761,432 ) ( 1,761,432 ) Balances at March 31, 2026 3,796,907 $ 3,797 11,450,045 $ 11,450 $ 72,093,902 $ ( 66,361,599 ) $ 5,747,550 Balance 3,796,907 $ 3,797 11,450,045 $ 11,450 $ 72,093,902 $ ( 66,361,599 ) $ 5,747,550 The accompanying notes are an integral part of these unaudited condensed financial statements 5 NeurAxis, Inc. Condensed Statements of Cash Flows (Unaudited) 2026 2025 For the Three Months Ended March 31, 2026 2025 Cash Flows from Operating Activities Net Loss $ ( 1,761,432 ) $ ( 2,278,684 ) Adjustments to reconcile net loss to net cash used by operating activities: Depreciation and amortization 16,317 6,356 Provisions for losses on accounts receivable ( 106 ) — Provisions for losses on inventory ( 6,476 ) — Loss on disposal of property and equipment — 533 Non-cash lease expense 16,215 13,719 Stock-based compensation 329,434 105,811 Issuance of common stock for non-cash consideration 50,001 — Change in fair value of warrant liabilities 31,506 ( 1,831 ) Changes in operating assets and liabilities: Accounts receivable ( 189,200 ) 910 Inventory 25,326 6,907 Prepaids and other current assets 39,119 25,840 Accounts payable 165,932 ( 61,931 ) Accrued expenses 68,213 156,784 Customer deposits 925 5,157 Operating lease liability ( 15,531 ) ( 14,823 ) Other non-current liabilities — 431,597 Net cash used in operating activities ( 1,229,757 ) ( 1,603,655 ) Cash Flows from Investing Activities Additions to property and equipment — ( 18,000 ) Net cash used in investing activities — ( 18,000 ) Cash Flows from Financing Activities Proceeds from issuance of common stock 2,990,361 — Proceeds from exercised warrants 507,035 — Offering costs paid ( 89,711 ) — Principal payments on notes payable ( 57,557 ) ( 69,845 ) Taxes paid related to net share settlement of restricted stock units ( 6,784 ) — Net cash provided by (used in) financing activities 3,343,344 ( 69,845 ) Net Increase (Decrease) in Cash and Cash Equivalents 2,113,587 ( 1,691,500 ) Cash and Cash Equivalents at Beginning of Period 4,965,072 3,696,870 Cash and Cash Equivalents at End of Period $ 7,078,659 $ 2,005,370 Supplemental Disclosure of Operating Activities Cash paid for interest $ 2,573 $ 2,237 Cash paid for income taxes — — Supplemental Schedule of Non-Cash Investing and Financing Activities Common stock issued for services $ 399,995 $ 112,493 Common stock issued upon cashless exercise of warrants — 186 Share settlement of restricted stock units, net of shares withheld for payment of payroll taxes 3 — Deferred offering costs reclassified to additional paid in capital upon completion of stock offering 20,720 — The accompanying notes are an integral part of these unaudited condensed financial statements 6 1. Basis of Presentation, Organization and Other Matters NeurAxis, Inc. (“we,” “us,” the “Company,” or “NeurAxis”) was established in 2011 and incorporated in the state of Indiana in 2012 under the name of Innovative Health Solutions, Inc. The name was changed to NeurAxis, Inc. in 2022 when the Company filed a Certificate of Conversion and became a Delaware corporation. The Company is headquartered in Carmel, Indiana, and specializes in the development, production, and sale of medical neuromodulation devices. The Company has developed four FDA cleared products: (i) the IB-STIM (DEN180057, 2019), (ii) the Rectal Expulsion Device (“RED”) (K242304,2024), (iii) the NSS-2 Bridge (DEN170018, 2017) and (iv) the original 510(K) clearance (K140530, 2014). ● The IB-STIM is a percutaneous electrical nerve field stimulator (PENFS) device that is indicated in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome and in patients 8 years and older with functional abdominal pain associated with functional dyspepsia and related nausea symptoms. ● RED is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity patients who experience desire or urge to defecate at lower volumes of distention. RED is intended to be used in a clinical setting by trained health care providers in adult populations. ● The NSS-2 Bridge is a percutaneous nerve field stimulator (PNFS) device indicated for use in the reduction of the symptoms of opioid withdrawal and was licensed to Masimo Corporation (“Masimo”). Masimo marketed and sold this product as its Masimo Bridge. On July 1, 2025, the Company terminated the NSS-2 Bridge license with Masimo in exchange for $ 200,000 of consideration payable in equal installments on December 31, 2025 and June 30, 2026. The termination agreement allowed the Company to recapture its rights to the trademark (U.S. Registration No. 7,394,465) and two patent applications (Application No. 18/821,225 and Application No. 29/960,608) that were licensed to Masimo on April 9, 2020. ● The original 510(K) device was an Electroacupuncture Device (“EAD”), now called NeuroStim. The EAD is no longer being manufactured, sold or distributed but reserved only for research purposes. The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and following the requirements of the U.S. Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These interim financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments which are necessary for a fair presentation of the Company’s financial information. These unaudited interim results are not necessarily indicative of the results to be expected for the year ending December 31, 2026, or any other interim period or for any other future year. These unaudited financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2025. 7 2. Summary of Significant Accounting Policies Use of Estimates and Critical Accounting Estimates and Assumptions The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. These significant accounting estimates or assumptions bear the risk of change due to uncertainties attached to these estimates or assumptions, and certain estimates or assumptions are difficult to measure or value. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. The Company uses estimates in accounting for, among other items, revenue recognition, allowance for credit losses, stock-based compensation, income tax provisions, excess and obsolete inventory reserve, impairment of property and equipment and intellectual property. Actual results could differ from those estimates. Reclassification of Prior Year Amounts Certain prior year amounts have been reclassified to conform to current period presentation. The Company reclassified $ 366,165 of general and administrative expenses to selling expenses in the Condensed Statements of Operations for the three months ended March 31, 2025. The Company also reclassified $ 57,311 of general and administrative expenses to research and development expenses in the Condensed Statements of Operations for the three months ended March 31, 2025. These reclassifications had no impact on previously reported net loss, total assets, total liabilities or total equity. Accounts Receivable and Allowance for Credit Losses Trade accounts receivable is stated at the amount management expects to collect from outstanding balances, net of an allowance for credit losses. Management evaluates many factors when determining the collectability of specific customer accounts, including, but not limited to, creditworthiness, past transaction and payment history, current economic industry trends and changes in payment terms. Management used assumptions and judgment based on the best available facts and circumstances to estimate and record an allowance. The Company monitors accounts receivable and estimates the allowance for lifetime expected credit losses. Estimates of expected credit losses are based on historical collection experience, aging schedule and other factor, including those related to current and forecasted market conditions and events. The allowance for credit losses was $ 7,220 and $ 7,326 as of March 31, 2026 and December 31, 2025, respectively. The Company recorded no credit loss expense for the three months ended March 31, 2026 and 2025. Inventories Inventories are valued at the lower of cost or net realizable value. Cost is determined using the weighted average method. The inventory is comprised of finished medical devices on hand. Certain components within the devices have an expiration date that are removed from current inventory and expensed at the date of expiration. The Company has reserved for expired inventory as charges to cost of goods sold of $ 758 and $ 0 for the three months ended March 31, 2026 and 2025, respectively. There was no reserve for research devices recorded as charges to research and development expenses for the three months ended March 31, 2026 and 2025, respectively. Inventory reserves totaled $ 28,048 and $ 34,524 as of March 31, 2026 and December 31, 2025, respectively. 8 Selling Expenses Selling expenses consist primarily of advertising, marketing and promotion of the Company’s products including salaries and related personnel costs and travel expenses. Advertising expenses are expensed as incurred and amounted to $ 29,821 and $ 85,348 for the three months ended March 31, 2026 and 2025, respectively. Research and Development Research and development expenses consist primarily of clinical research studies, new product development, costs of materials and supplies used in research and development activities and salaries and related personnel costs for employees engaged in research and development activities to have our IB-Stim and RED devices cleared by the FDA for other indications. Research and development costs are expensed as incurred. Intangible Assets Intangible assets consist of software, patents, a trademark and a license. Intangible assets are stated at their historical cost and amortized on a straight-line basis over their expected useful lives. Capitalized patent costs, net of accumulated amortization, includes legal costs incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write off any capitalized patent costs at that time. The Company purchased a trademark related to the Company’s name for $ 50,000 . The trademark does not have a determinate life and therefore the cost is not being amortized. On July 1, 2025, the Company terminated the NSS-2 Bridge license with Masimo in exchange for $ 200,000 of consideration payable in equal installments on December 31, 2025, and June 30, 2026. The termination agreement allowed the Company to recapture the rights to the trademark (U.S. Registration No. 7,394,465) and two patent applications (Application No. 18/821,225 and Application No. 29/960,608) that were licensed to Masimo on April 9, 2020 for use in the reduction of the symptoms of opioid withdrawal. The intellectual property is amortized over its remaining trademark life of approximately nine years. Fair Value Measurements The Company accounts for financial instruments in accordance with Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures , which establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described as follows: Level 1 – Quoted prices (unadjusted) for identical unrestricted assets or liabilities in active markets that the reporting entity has the ability to access as of the measurement date. Level 2 – Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or financial instruments for which all significant inputs are observable or can be corroborated by observable market data, either directly or indirectly. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. These unobservable inputs reflect that reporting entity’s own assumptions about what market participants would use in pricing the asset or liability. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value require significant management judgment or estimation. Management believes the estimated fair value of certain accounts including cash, accounts receivable, account payable and other current assets on March 31, 2026, and December 31, 2025, approximate their carrying value as reflected in the balance sheets due to the short-term nature of these instruments or the use of market interest rates for debt instruments. 9 The Company’s Level 3 accounts include warrant liabilities and the floating lookback option provision in the Neuraxis, Inc. Employee Stock Purchase Plan. Inputs to determine fair value are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques, including option pricing and discounted cash flow models. The valuation techniques involve management’s estimates and judgment based on unobservable inputs. The fair value estimates may not be indicative of the amounts that would be realized in a market exchange. Additionally, there may be inherent uncertainties or changes in the underlying assumptions used, which could significantly affect the current or future fair value estimates. Unobservable inputs used in the models are significant to the fair values of the assets and liabilities. There were no transfers between any of the levels during the three months ended March 31, 2026 and 2025. In addition to assets and liabilities that are recorded at fair value on a recurring basis, the Company had no assets that were measured on a nonrecurring basis as of March 31, 2026 and December 31, 2025. Basic and Diluted Net Income (Loss) per Share Basic earnings or loss per share (“EPS”) is computed by dividing net income (loss), net of preferred stock dividends, by the weighted average number of common shares outstanding during the period. Diluted EPS is determined using the weighted average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents that were outstanding for the periods presented. In periods when losses are reported, which is the case for the three month periods ended March 31, 2026 and 2025 presented in these financial statements, the weighted average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. Preferred stock dividends (neither declared nor paid) were $ 1,215,264 and $ 1,025,865 as of March 31, 2026 and December 31, 2025, respectively. The Company had the following potentially dilutive common stock equivalents: Schedule of Dilutive Common Stock Equivalents 2026 2025 March 31, 2026 2025 Options 1,319,394 1,319,394 Restricted Stock Units 1,265,443 842,214 Warrants 1,166,484 2,139,883 Series B Preferred Stock 3,796,907 4,280,939 Undeclared Cumulative Series B Preferred Stock Dividends 510,615 178,492 Totals 8,058,843 8,760,922 The following table presents the calculation of the basic and diluted net loss per share and the effect of preferred stock dividends: Schedule of Basic and Diluted Net Loss Per Share 2026 2025 Three Months Ended March 31, 2026 2025 Numerator: Net loss $ ( 1,761,432 ) $ ( 2,278,684 ) Preferred stock dividends ( 189,399 ) ( 213,543 ) Net loss available to common stockholders ( 1,950,831 ) ( 2,492,227 ) Denominator: Weighted average shares of common stock outstanding - basic and diluted 10,948,121 7,463,578 Basic and diluted net loss per share $ ( 0.18 ) $ ( 0.33 ) 10 Stock-Based Compensation The Company accounts for all stock-based awards at fair value. The Company recognizes its stock-based compensation expense using the straight-line method. Compensation cost is not adjusted for estimated forfeitures, but instead is adjusted upon actual forfeiture. The Company accounts for the granting of stock options and restricted stock units to employees and non-employees using the fair value method whereby all awards are measured at fair value on the date of the grant. The fair value of all employee stock options and restricted stock units is expensed over the requisite service period with a corresponding increase to additional paid-in capital. Upon exercise of stock options, the consideration paid by the option holder is recorded in additional paid-in capital, while the par value of the shares received is reclassified from additional paid-in-capital to common stock. Upon vesting of restricted stock units, the par value of the shares issued are reclassified from additional paid-in-capital to common stock. Stock-based awards to non-employees are measured based on the fair value of the equity instrument issued. Compensation expense for non-employee stock awards is recognized over the requisite service period following the measurement of the fair value on the grant date. The Company uses the Black-Scholes option-pricing model to calculate the fair value of stock options and the Monte Carlo simulation model to calculate the fair value of the floating lookback option with the Neuraxis, Inc. 2025 Employee Stock Purchase Plan. The use of these option-pricing models requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend yield of the common stock. Changes in these assumptions can materially affect the fair value estimate. Revenue Recognition In accordance with ASC 606, Revenue from Contracts with Customers , the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, it (i) identifies the contract(s) with a customer, (ii) identifies the performance obligations in the contract, (iii) determines the transaction price, (iv) allocates the transaction price to the performance obligations in the contract and (v) recognizes revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts when it determines that it is probable it will collect substantially all the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price, after consideration of variability and constraints, if any, that is allocated to the respective performance obligation when the performance obligation is satisfied. The Company offers a patient assistance program for patients without insurance coverage for IB-Stim. This program extends potential self-pay discounts for IB-Stim devices, based upon household income and size. Certain economic factors affect the nature, amount, timing, and uncertainty of the Company’s revenue and cash flows. All of the Company’s products are sold to healthcare customers including hospitals, clinics and physician offices. Sales to healthcare customers lack seasonality and have a mild correlation with economic cycles. All of the Company’s sales are to customers located within the United States. Sales contracts consist of purchase orders that are short-term (i.e., less than or equal to one year). 11 The Company typically satisfies its performance obligations for goods at a point in time as they are received at the customer’s destination (rather than over time). Goods are shipped by common carrier to customers under FOB destination terms. As such, ownership of goods in transit is transferred to the customer upon receipt as the Company bears the associated risks (e.g., loss, damage or delay). Management typically relies on shipping information from common carriers to evaluate when the customer has obtained control of the goods. Shipping and handling costs are recorded as cost of goods sold in the Condensed Statements of Operations. The Company’s contracts with customers typically do not involve variable consideration. The information that the Company uses to determine the transaction price for a contract is similar to the information that the Company’s management uses in establishing the prices of goods to be sold. Orders may not be cancelled after shipment. Customers may return devices within 10 days of delivery if the goods are found to be defective, nonconforming, or otherwise do not meet the stated technical specifications. At the option of the customer, the Company shall either: ● Refund the price paid for any defective or nonconforming products. ● Supply and deliver to the customer replacement conforming products. ● Reimburse the customer for the cost of repairing any defective or nonconforming products. At the time revenue is recognized, the Company estimates expected returns and excludes those amounts from revenue. The Company also maintains appropriate accounts to reflect the effects of expected returns on the Company’s financial position and periodically adjusts those accounts to reflect its actual return experience. Estimated returns totaled $ 33,261 and $ 13,824 as of March 31, 2026 and December 31, 2025, respectively. Payment for goods sold by the Company is typically due after an invoice is sent to the customer, within 30 days. The Company does not offer discounts if the customer pays some or all of an invoiced amount prior to the due date. None of the Company’s contracts have a significant financing component. Medical devices that the Company contracts to sell and transfer to customers are manufactured by two third-party manufacturers located in Indiana and Michigan. In no case does the Company act as an agent (i.e., the Company does not provide a service of arranging for another party to transfer goods to the customer). Going Concern As of March 31, 2026, the Company had stockholders’ equity of $ 5,747,550 and short-term outstanding borrowings of $ 100,735 . Additionally, the Company had cash of $ 7,078,659 and a working capital surplus of $ 5,328,867 as of March 31, 2026. However, we have incurred losses and negative cash flows from operations since inception and have funded our operations primarily with a combination of sales, debt, and proceeds from the issuance of capital stock. Our future capital requirements will depend upon many factors, including progress with developing, manufacturing, and marketing our technologies, the time and costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other proprietary rights, our ability to establish collaborative arrangements, marketing activities and competing technological and market developments, including regulatory changes and overall economic conditions in our target markets. Our ability to generate revenue and achieve profitability requires us to successfully market and secure purchase orders for our products from customers currently identified in our sales pipeline and to new customers as well. The primary activity that will drive all customers and revenues is the adoption of insurance coverage by commercial insurance carriers nationally, which is a top priority of the Company. These activities, including our planned research and development efforts, will require significant uses of working capital through the rest of 2026 and beyond. 12 Management evaluates whether there are conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date the financial statements are issued. While the Company believes in the viability of its strategy to further implement its business plan and generate sufficient revenues and in its ability to raise additional funds by way of a public or private offering of its debt or equity securities, there can be no assurance that it will be able to do so on reasonable terms, or at all. The ability of the Company to continue as a going concern is dependent upon its ability to further implement its business plan and generate sufficient revenues and its ability to raise additional funds by way of a public or private offering. Neither future cash generated from operating activities, nor management’s contingency plans to mitigate the risk and extend cash resources through the evaluation period, are considered probable. As a result, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern. As the Company continue to incur losses, the transition to profitability is dependent upon achieving a level of revenues adequate to support its cost structure. We may never achieve profitability, and unless and until doing so, we intend to fund future operations through additional dilutive or nondilutive financing. There can be no assurances, however, that additional funding will be available on terms acceptable to us, if at all. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Recently Adopted Accounting Standards In July 2025, the FASB issued ASU 2025-05, Financial Instruments—Credit Losses (Topic 326) , which allows registrants to elect a practical expedient when estimating expected credit losses on accounts receivable. Under the practical expedient, an entity may assume that the current conditions as of the balance sheet date persist for the remaining life of the asset, thereby removing the requirement to generate forward-looking forecasts. All entities are required to adopt the standard prospectively for fiscal years beginning after December 15, 2025, and interim periods within those annual reporting periods. The Company adopted the provisions of ASU 2025-05 as of January 1, 2026, on a prospective basis. The Company did not elect the practical expedient and the adoption of the standard did not have a material impact on the Company’s financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which requires the enhancement of income tax disclosures to provide better insight into how an entity’s operations and related tax risks, planning and opportunities affect its tax rate and prospects for future cash flows. The enhanced disclosures require (i) specific categories in a tabular rate reconciliation including both amounts and percentages and (ii) additional information for reconciling items and income tax paid that meet a quantitative threshold. Public business entities are required to adopt the standard for annual periods beginning after December 15, 2024. The Company adopted the disclosure provisions of ASU 2023-09 as of December 31, 2025, on a prospective basis. The adoption of this standard did not have a material impact on the Company’s financial statements. Recently Issued Accounting Standards In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270), which provides a comprehensive list of interim disclosures that are required by U.S. GAAP to provide clarity on current requirements. Public business entities are required to adopt the standard for interim periods within annual reporting periods beginning after December 15, 2027. The adoption is not expected to have a material impact on the Company’s financial statements. In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvement to the Accounting for Internal-Use Software , which replaces project stage milestones with required capitalization when management has authorized and committed to funding the software project and it is probably that the project will be completed and the software will be used to perform the function intended. Depreciation expense and accumulated depreciation for internal-use software are also required to be disclosed for all periods presented. All entities are required to adopt the standard for fiscal years beginning after December 15, 2027 and interim periods within those annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period. The adoption is not expected to have a material impact on the Company’s financial statements. In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic (220-40): Disaggregation of Income Statement Expenses , which requires disclosures that disaggregate, in a tabular presentation, each relevant expense caption on the face of the income statement that includes inventory purchases, employee compensation, depreciation and intangible amortization expense. Additional disclosures are also required to provide a qualitative description of the amounts in an expense caption that are not separately disaggregated quantitatively and the total amount of selling expenses including a definition. Public business entities are required to adopt the standard for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Disclosures are required for all prior periods presented in the financial statements. Although the standard requires enhanced disclosures, the adoption is not expected to have a material impact on the Company’s financial statements. 13 3. Related Party Transactions The Company has two demand notes receivable from shareholders related to the sale of common stock on January 1, 2016. Both notes’ principal balances are $ 506,400 , with interest calculated monthly based on applicable federal rates. No payments have been received on the notes. Since repayment is not assured, the Company has fully reserved for the entire balance of principal and interest. The current allowance is $ 1,250,388 and $1,241,559 as of March 31, 2026 and December 31, 2025, respectively. The current loan balances are as follows: Schedule of Related Party Transactions March 31, 2026 December 31, 2025 Loan Interest Interest Loan Interest Interest Receivable Receivable Income Receivable Receivable Income Shareholder 1 $ 506,400 $ 118,861 $ 4,414 $ 506,400 $ 114,447 $ 20,096 Shareholder 2 506,400 118,727 4,414 506,400 114,312 20,096 Principal balance 1,012,800 237,588 8,828 1,012,800 228,759 40,192 Allowance for collection risk ( 1,012,800 ) ( 237,588 ) ( 8,828 ) ( 1,012,800 ( 228,759 ) ( 40,192 ) Net balance $ — $ — $ — $ — $ — $ — The Company has loans payable to shareholders related to funding needs for operations. The current loan details for all related party loans are as follows: Schedule of Related Party Loans payable to shareholder Interest & Interest Loan Service Fee Interest March 31, 2026 Due Date Rate Balance Accrued Paid Other Convertibles Various 5.0 % — 66,648 — Total $ — $ 66,648 $ — Interest & Interest Loan Service Fee Interest December 31, 2025 Due Date Rate Balance Accrued Paid Other Convertibles Various 5.0 % — 66,648 — Total $ — $ 66,648 $ — The Company was granted an exclusive, worldwide non-transferable, royalty-free license for the auricular portion of certain patents owned by a limited liability company in which the Company’s President and Chief Executive Officer and Chief Regulatory, Compliance and Privacy Officer both maintain an ownership interest. The license allows for the development, marketing and sales of electro-therapy treatments by stimulation of cranial nerves, cranial nerve branches, auricular nerves, auricular nerve branches, auricular nerve bundles and auricular anatomical structures in human patients. The exclusive license agreement expires on October 18, 2037, may be terminated by either party upon 60 days prior written notice and requires the Company to pay costs associated with the maintenance, prosecution and continuation of patent filings. The Company’s Board of Directors pre-approved the reimbursement of up to $ 20,000 for the year ending December 31, 2026. License costs totaled $ 453 and $ 1,317 for the three months ended March 31, 2026 and 2025, respectively. The Company owed the limited liability company $ 453 and $ 0 that are included in accounts payable in the Condensed Balance Sheets as of March 31, 2026 and December 31, 2025, respectively. From time to time, a member of the Company’s Board of Directors purchases NeuroStim devices from the Company at cost to conduct research and development activities. The Company’s Board of Directors pre-approved the sale of these NeuroStim devices up to $ 20,000 for the year ended December 31, 2026. The Company sold NeuroStim devices totaling $ 1,515 and $ 1,957 for the three months ended March 31, 2026 and 2025, respectively, under this program. 4. Prepaids and Other Current Assets Prepaids and other current assets consisted of the following: Schedule of Prepaids and Other Current Assets March 31, 2026 December 31, 2025 Prepaid insurance $ 85,680 $ 141,299 Prepaid software subscriptions 89,103 103,390 Other 266,292 70,594 Total prepaids and other current assets $ 441,075 $ 315,283 14 5. Other Non-Current Assets Other non-current assets consisted of the following Schedule of Other Non-Current Assets March 31, 2026 December 31, 2025 Security deposit $ 20,163 $ 20,163 Deferred offering costs 3,144 23,864 Prepaid software subscriptions — 14,912 Total other non-current assets $ 23,307 $ 58,939 6. Accrued Expenses Accrued expenses consisted of the following: Schedule of Accrued Expenses March 31, 2026 December 31, 2025 Compensation and benefits $ 1,232,230 $ 1,359,993 Settled litigation 528,799 692,683 NSS-2 Bridge lease termination fee 100,000 100,000 Legal fees 78,550 65,714 Interest 66,648 66,648 Research and development fees 61,204 2,143 Audit fees 52,500 — Tariffs 50,447 32,000 Other 91,069 74,048 Total accrued expenses $ 2,261,447 $ 2,393,229 7. Notes Payable On August 9, 2025, the Company entered into a $ 170,000 note payable to finance the premiums of a business insurance policy, bearing interest at an annual interest rate of 7.45 % and maturing on June 9, 2026 , to replace the $ 210,000 note payable entered into on August 9, 2024, with an annual interest rate of 7.40 % that matured on June 9, 2025 in conjunction with the annual renewal period. On May 26, 2025, the Company also entered into a note payable with a principal balance of $ 122,253 to finance subscription fees on certain software arrangements maturing on March 1, 2027. The outstanding principal was $ 100,735 and $ 148,293 as of March 31, 2026 and December 31, 2025, respectively. Interest expense totaled $ 26,189 and $ 2,237 for the three months ended March 31, 2026 and 2025, respectively. The Company’s accrued interest totaled $ 66,648 as of March 31, 2026 and December 31, 2025. 8. Leases The Company’s leases are comprised of operating leases for office space. At the inception of the lease, the Company determines whether the lease contract conveys the right to control the use of identified property for a period of time in exchange for consideration. Leases are classified as operating or finance leases at the commencement date of the lease. Operating leases are recorded as operating lease right-of-use assets, other current liabilities, and operating lease liabilities in the Condensed Balance Sheets. The Company did not have any finance leases at March 31, 2026 and December 31, 2025. The Company has two leases consisting of office space in Batesville and Carmel, Indiana. The lease in Batesville, Indiana commenced on August 1, 2025, and has an initial term of three years, with automatic one-year renewals subject to an annual 4% rent escalation, unless 60-day notice of vacating is given. On May 19, 2025, the Company terminated its prior lease in Versailles, Indiana, with a monthly lease payment of $ 1,800 , effective July 31, 2025, without penalty due to relocation of the office space to Batesville, Indiana, with the same landlord. The current monthly lease payment is $ 2,000 with no escalations during the initial lease term. On June 13, 2025, the Company prepaid $ 25,200 towards the monthly lease payments which will be amortized over the initial lease term. The lease in Carmel, Indiana commenced January 1, 2024, with an initial term of five years and five months. The monthly lease payment started at $ 6,721 with an annual increase of 2.5 %. The Company was only obligated to pay an amount equal to 50% of the monthly base rent for the first 10 months of the term. The Company recognized operating lease expense of $ 26,116 and $ 25,523 for the three months ended March 31, 2026 and 2025, respectively, including short-term lease expense and variable lease costs. 15 The following table presents information related to the Company’s operating leases: Schedule of Operating Leases March 31, 2026 December 31, 2025 Operating lease right of use asset, net $ 245,350 $ 261,565 Current portion of operating lease payable 68,789 65,752 Operating lease payable, net of current portion 183,998 202,566 Total operating lease payable $ 252,787 $ 268,318 Weighted-average remaining lease term (in years) 3.07 3.31 Weighted-average discount rate 15.0 % 15.0 % As of March 31, 2026, the maturities of the Company’s operating lease liabilities were as follows: Schedule of Maturities Operating Lease Liabilities Remainder of 2026 $ 75,261 2027 102,456 2028 98,127 2029 38,025 Total lease payments 313,869 Less: imputed interest ( 61,082 ) Total present value of lease payments $ 252,787 9. Common Stock and Warrants The Company has authorized 100,000,000 shares of common stock, of which 11,450,045 and 10,652,812 shares were issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. On January 22, 2026, the Company issued 43,196 shares of common stock with a fair value of $ 199,995 to its Board of Directors for their services for the year ending December 31, 2026. The Company recorded $ 50,000 as general and administrative expense in the Condensed Statements of Operations for the three months ended March 31, 2026 and $ 149,995 as prepaids and other current assets in the Condensed Balance Sheet as of March 31, 2026. On January 22, 2026, the Company issued another 43,196 shares of common stock with a fair value of $ 200,000 to its Board of Directors for their service during the year ended December 31, 2025. The Company recorded $ 50,000 as general and administrative expense in the Condensed Statements of Operations for the three months ended March 31, 2025. During the three months ended March 31, 2026, pursuant to the August 2025 At The Market Offering Agreement, the Company issued 495,456 shares of common stock to investors for gross proceeds of $ 2,990,361 with such shares registered pursuant to the Company’s effective Registration Statement on Form S-3 (File No. 333-283798), previously filed with the Securities and Exchange Commission (“SEC”) on December 13, 2024, and declared effective on February 11, 2025, and the related prospectus supplements filed with the SEC on August 29, 2025, and on October 23, 2025. Additionally, during the three months ended March 31, 2026, the Company issued (i) 213,040 common shares upon the exercise of warrants and (ii) 2,345 common shares pursuant to the 2022 Omnibus Securities and Incentive Plan. During the three months ended March 31, 2025, the Company issued (i) 39,471 shares of common stock with a fair value of $ 112,493 to its Board of Directors for their service from April 1, 2024 through December 31, 2024, which was recorded as general and administrative expense in the Condensed Statements of Operations and (ii) 186,166 shares of common stock to an investor in exchange for 502,647 warrants in a cashless exercise transaction with $ 186 reclassified from additional paid in capital to common stock in the Condensed Statements of Stockholders’ Equity. 16 The following is a summary of warrant activity for common stock during the three months ended March 31, 2026 and year ended December 31, 2025: Schedule of Warrant Activity for Common Stock Number of Weighted-Avg. Weighted-Avg. Warrants for Exercise Remaining Common Stock Price Contractual Life Outstanding as of January 1, 2025 2,642,530 $ 2.41 2.93 Exercised ( 1,263,006 ) 1.82 2.12 Outstanding as of December 31, 2025 1,379,524 2.44 2.26 Exercised ( 213,040 ) 2.38 1.94 Outstanding as of March 31, 2026 1,166,484 $ 2.45 2.04 The following table summarizes the Company’s warrants outstanding and exercisable as of March 31, 2026: Schedule of Warrants outstanding and Exercisable Number of Warrants Exercise Expiration Outstanding Price Date Investor Warrant 12,852 $ 8.76 September 18, 2028 2022 Convertible Notes 160,960 $ 2.38 Various in 2027 2023 Convertible Notes 861,790 $ 2.38 Various in 2028 Underwriter Warrants 54,370 $ 2.38 August 8, 2028 Advisory Agreement Warrants 76,512 $ 2.38 Various in 2029 1,166,484 10. Preferred Stock The Company’s shareholders authorized 5,000,000 shares of preferred stock of which 5,000,000 shares were designated as $ 0.001 par value Series B Preferred Stock with 3,796,907 shares issued and outstanding as of March 31, 2026 and December 31, 2025. Series B Preferred Stock shareholders vote with Common Stock shareholders on an as-converted basis and not as a separate class. Cumulative dividends accrue at 8.5 % per annum and are due and payable in either cash for common shares as the Company’s discretion on a quarterly basis through December 31, 2026. Series B Preferred Stock converts to common stock on a 1:1 basis, subject to adjustments for stock dividends, splits, combinations and similar events as well as unpaid dividends thereon, solely at the election of the holder at any time. Upon any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, the Series B Preferred Stock shareholders maintain priority preference over all other classes of capital stock. A merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) and a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of the Company will be treated as a liquidation event, thereby triggering payment of the liquidation preferences. As of March 31, 2026 and December 31, 2025, there were no preferred stock dividends declared or paid. Series B Preferred Stock undeclared cumulative dividends totaled $ 1,215,264 and $ 1,025,865 as of March 31, 2026 and December 31, 2025, respectively. 17 11. Stock-Based Compensation Restricted Stock Units Pursuant to the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the Company initiated grants of restricted stock units (“RSUs”) to certain employees as follows: Schedule of Restricted Stock Units Three Months Ended March 31, 2026 2025 Number of RSUs Weighted Average Fair Value Number of RSUs Weighted Average Fair Value Outstanding as of Beginning of Period 831,346 $ 2.32 — $ — Granted 437,431 4.63 852,214 2.31 Vested ( 3,334 ) 2.36 — — Outstanding as of End of Period 1,265,443 $ 3.12 852,214 $ 2.31 The RSUs granted during the three months ended March 31, 2026 are subject to a pro rata annual vesting period over 3 years whereas the RSUs granted during the three months ended March 31, 2025 are subject to a three-year cliff vesting period. The RSUs are payable in shares of the Company’s common stock and fully vest upon (i) death or disability or (ii) change of control. Dividend equivalents accrue on RSUs and are paid upon vesting; there were no accrued dividends on unvested RSUs as of March 31, 2026. Total stock-based compensation expense related to RSUs is classified in the Company’s Condensed Statements of Operations as general and administrative expense and amounted to $ 329,434 and $ 105,811 for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, total unrecognized stock-compensation expense relating to unvested stock awards granted under the Company’s share-based compensation plans amounted to $ 2,864,172 . Stock Options The following is a summary of the Company’s outstanding stock options as of March 31, 2026 and December 31, 2025: Schedule of Stock Option Activity Number of Options Weighted Avg. Remaining Contractual Life (in years) Weighted Avg. Exercise Price Aggregate Intrinsic Value Outstanding as of December 31, 2025 1,319,394 3.69 $ 6.94 $ — Outstanding as of March 31, 2026 1,319,394 3.44 $ 6.94 $ — Vested and Exercisable as of March 31, 2026 1,319,394 3.44 $ 6.94 $ — There was no stock-based compensation expense related to stock options recorded for the three months ended March 31, 2026 and 2025. 18 Employee Stock Purchase Plan On July 1, 2025, the Compensation Committee of the Board of Directors (“Board”) of the Company adopted the NeurAxis, Inc. 2025 Employee Stock Purchase Plan (the “ESPP”), effective as of the same date and subject to Shareholder approval by July 1, 2026. The purpose of the ESPP is to provide eligible employees an opportunity to acquire common stock of the Company at a 15% discount using payroll deductions. The maximum number of shares of the Company’s common stock that may be issued under the ESPP is 100,000, subject to an annual increase on January 1st of each year from 2026 through 2035 by the lesser of (i) 1% of the Company’s outstanding capital stock as of the prior December 31st or (ii) 100,000 shares. The Board may reduce or eliminate this annual increase before February 1st of any given year. Total stock-based compensation expense includes $ 37,329 and $ 0 relating to the ESPP for the three months ended March 31, 2026 and 2025, respectively. Employee withholdings of $96,604 and $13,611 are included in accounts payable in the Condensed Balance Sheets as of March 31, 2026 and December 31, 2025, respectively. 12. Warrant Liabilities The Company has evaluated financial instruments arising from warrants that are issued and outstanding as of March 31, 2026 and December 31, 2025. The Company utilizes a Black-Scholes option-pricing model to compute the fair value of the liability and to mark to market the fair value of the warrant at each balance sheet date. The inputs utilized in the application of the Black-Scholes option-pricing model included (i) an exercise price of $ 8.76 per share, (ii) an expected remaining term of each warrant based on the remaining contractual maturity of the each warrant, (iii) estimated volatility ranging from 89.1 % to 94.7 % based on historical stock prices of comparable companies with a look back period commensurate with the period to maturity, (iv) a risk-free interest rate ranging from 3.72 % to 3.96 % based on the interest rates of U.S. Treasury Notes consistent with the expected remaining contract term and (v) a 0 % expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future. The following are the changes in the warrant liabilities during the three months ended March 31, 2026 and year ended December 31, 2025: Schedule of Changes in Warrant Liabilities Level 3 Warrant liabilities as of January 1, 2025 $ 9,166 Changes in fair value of warrant liabilities 7,634 Warrant liabilities as of December 31, 2025 16,800 Changes in fair value of warrant liabilities 31,506 Warrant liabilities as of March 31, 2026 $ 48,306 13 . Segment Information The Company evaluates the following factors to identify its reportable segments: (i) nature of products and services, (ii) type of customer for the products and services, (iii) sales, production and distribution methods of the products and services and (iv) the nature of the regulatory environment, if applicable. Based on an evaluation of these factors, management concluded that the Company’s operations are managed through one reportable segment, IB-STIM, that derives its revenues in the United States from a PENFS device that is used to treat patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome and in patients 8 years and older with functional abdominal pain associated with functional dyspepsia and related nausea symptoms. The accounting policies of the IB-STIM segment are the same as those described in the Summary of Significant Accounting Policies (see Footnote 2). The Chief Operating Decision Maker (“CODM”) regularly evaluates the performance of the IB-STIM segment for the purpose of allocating resources based on net sales and operating loss, both of which are reported in the Condensed Statements of Operations. The CODM uses net sales to evaluate IB-STIM’s adoption and utilization by insurance carriers and physicians. As Neuraxis is an emerging growth company, operating loss is used to monitor the Company’s cost structure in order to achieve future segment profitability. Both net sales and operating loss are measured against the budget on a periodic basis to assess achievement toward annual compensation incentive targets. The Company’s CODM is its Chief Executive Officer. 19 The following reconciles the reportable segment net sales and operating loss to the Company’s reported net loss: Schedule of Reconciles the Company’s Net Sales and Operating Loss 2026 2025 Three months ended March 31, 2026 2025 Net Revenue $ 1,607,883 $ 895,655 COGS 218,366 139,475 Gross Profit 1,389,517 756,180 Selling Expenses (a) 824,336 500,119 Research & Development (a) 99,567 117,867 Compensation and Benefits (a) 1,412,665 1,075,244 Professional Services (a) 436,303 406,716 Legal Settlement - 619,097 Depreciation 8,034 3,735 Amortization 8,284 2,621 Other Operating Expenses (a) (b) 341,007 325,879 Segment Operating Loss ( 1,740,679 ) ( 2,295,098 ) Interest Expense ( 26,189 ) ( 2,237 ) Change in Fair Value of Warrant Liability ( 31,506 ) 1,831 Other Income 36,942 16,820 Total Other (Expense) Income, Net ( 20,753 ) 16,414 Net Loss $ ( 1,761,432 ) $ ( 2,278,684 ) (a) The significant expense categories and amounts align with the segment-level information provided on a regular basis to the CODM. (b) Other operating expenses include rent and utilities, insurance, travel, software subscription fees, board fees and bad debt expense. Total segment assets for IB-STIM amounted to $ 8,745,706 and $ 6,404,036 as of March 31, 2026 and December 31, 2025, respectively. Total segment capital expenditures for IB-STIM amounted to $ 0 and $ 18,000 for the three months ended March 31, 2026 and 2025, respectively. Total segment depreciation and amortization amounted to $ 16,317 and $ 6,356 for the three months ended March 31, 2026 and 2025, respectively. Significant segment non-cash charges settled in common stock include (i) consulting and advisory fees totaling $ 399,995 and $ 112,493 for the three months ended March 31, 2026 and 2025, respectively, and (ii) hiring grants totaling $ 5,534 and $ 0 for the three months ended March 31, 2026 and 2025, respectively. 14. Settled Litigation On February 6, 2019, plaintiff Ritu Bhambhani, M.D., initiated a lawsuit against Innovative Health Solutions, Inc. and others in the United States District Court for the District of Maryland. Plaintiffs Bhambhani and Sudhir Rao subsequently amended the complaint, with the Third Amended Complaint (“Complaint”) containing the most recent set of allegations. The Complaint asserted claims under the RICO Act, as well as of fraudulent misrepresentation, intentional misrepresentation by concealment, and civil conspiracy and sought compensatory damages in excess of $ 5 million, pre-judgment interest, punitive damages, attorney’s fees, court costs and designation of the case as a class action. The Complaint stated that the Company, distributors of the Company’s product, and medical billing and coding consultants allegedly made misrepresentations to the plaintiffs that the Company’s NeuroStim device and related procedures could be billed to, and reimbursed by, Medicare and other insurance payors as a surgically implantable neurostimulator. Plaintiffs claim to have suffered damages when Medicare administrative contractors declined to pay plaintiffs for their use of the device. On February 11, 2022, the Company filed a motion for summary judgment based upon the plaintiffs not being proper parties to assert claims against the Company. On June 14, 2022, the Court granted the Company’s motion for summary judgment and dismissed the Complaint. On July 14, 2022, plaintiffs Ritu Bhambhani and Sudhir Rao filed a notice of appeal with the Fourth Circuit Court of Appeals. On June 3, 2024, the Fourth Circuit denied the plaintiff’s appeal and entered judgment against the plaintiffs. On June 25, 2024, the Fourth Circuit entered its mandate declaring that its judgment against the plaintiffs took effect that day. The plaintiffs did not seek any further review or appeal of that judgment. 20 Also on July 14, 2022, plaintiffs Ritu Bhambhani, LLC; Box Hill Surgery Center, LLC; Pain and Spine Specialists of Maryland, LLC; and SimCare ASC, LLC initiated a lawsuit against the Company and others in the United States District Court for the District of Maryland. The plaintiffs in this lawsuit are business entities owned or partially owned by the plaintiffs that initiated the litigation described above. The Complaint asserted claims under the RICO Act, as well as fraudulent misrepresentation, intentional misrepresentation by concealment, and civil conspiracy and seeks compensatory damages in excess of $ 75,000 , pre-judgment interest, punitive damages, attorney’s fees, and court costs. The Complaint states that the Company, distributors of the Company’s product, and medical billing and coding consultants allegedly made misrepresentations to the plaintiffs that the Company’s NeuroStim device and related procedures could be billed to, and reimbursed by, Medicare and other insurance payors as a surgically implantable neurostimulator. Plaintiffs claim to have suffered damages when Medicare administrative contractors declined to pay plaintiffs for their use of the device. On September 28, 2022, the Company filed a motion to dismiss all claims. On May 25, 2023, the Court issued an Order and a Memorandum Opinion which dismissed the plaintiffs’ claims related to the RICO Act. The remaining claims are still pending, and no trial date has been set for the case. The Court has vacated its Scheduling Order at the parties’ request so that the parties could try to resolve the disputes in both cases through an independent third-party mediator. On April 25, 2025, the parties reached a $ 750,000 settlement payable in 12 equal monthly installments that began in January of 2026. The Company recorded a charge of $ 619,097 classified as general and administrative expense in the Condensed Statements of Operations during the three months ended March 31, 2025, while interest expense was recorded as incurred. As of March 31, 2026, the Company maintained a liability of $ 528,799 classified as accrued expenses in the Condensed Balance Sheets. 15 . Commitments and Contingencies Manufacturing Services Agreement The Company is party to two separate manufacturing services agreements for the manufacture and supply of the Company’s IB-Stim and RED devices based on the Company’s product specifications that expire in March and August, 2027, respectively, and automatically renew annually unless either party provides a written termination notice to the other party within 180 days prior to the end of the then-current term. The Company’s IB-Stim and RED devices are manufactured in Indiana and Michigan, respectively. The Company provides the necessary equipment to the manufacturers and retains ownership. The manufacturers bear the risk of loss of and damage to the equipment and consigned materials. Performance under the agreement is initiated by orders issued by the Company and accepted by the manufacturers. The Company also entered into quality agreements with the manufacturers to perform quality assurance services on product provided by the Company. Executive Employment Agreements The Company, as authorized by the board of directors, entered into employment agreements with certain employees to provide incentives to improve shareholder value and to contribute to the growth and financial success of the Company. The agreements had an employment start date of October 1, 2022, with initial terms from two 2 to five years and optional one-year renewals . There are nine key employees and two non-employees that have stock options of the Company totaling 1,319,394 shares. These key employees have a provision in their agreements whereas the Company will pay a special bonus equal to the aggregate of the strike price or exercise price of all their stock options plus a tax gross-up payment. The special bonus shall be paid in twenty percent ( 20 %) installments starting January 2, 2024, and the same date each of the next four years. As a condition of the payment, the key employee must exercise at least 20 % of their stated number of stock options. There are additional provisions to cover termination and change of control events. None of the key employees have exercised any of the stock options as of March 31, 2026. 21 In April 2023, the Company amended the employee agreements to, among other things, clarify that the special one-time incentive payment and the deferred bonus are contingent upon the effective date of the planned initial public offering. The amendment also sets forth a process for executives to exercise the stock options in accordance with the terms of the stock option agreement in effect as of the date of the employment agreement and to clarify that there is no modification to the stock option agreements. The Company recorded the fair value of the stock options totaling $ 5,610,234 as compensation cost on the grant date. In addition, a $ 6,225,169 incremental tax gross up payment is contingent upon the employees exercising their deferred bonus provision which will be recorded when probable. Threatened Litigation From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of the date of issuance, other than those described below and in note 13, there were no pending or threatened legal proceedings that could reasonably be expected to have a material effect on the results of the Company’s operations. There are also no proceedings in which any of the Company’s directors, officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company’s interest. Legal fees are expensed as incurred. In January 2024, Dr. Arturo Taca served notice to the Company that asserted an interest in its U.S. Patent No. 10,413,719 valued at $ 2,000,000 based on his own work in neurostimulation. The Company denied both the neurostimulation patent and compensation claims. The case remains unresolved. While it is too early to predict the ultimate outcome of this matter, we believe the Company has meritorious defenses and intends to defend this matter vigorously. 16. Subsequent Events On April 1, 2026, the Company issued 43,885 shares of common stock to eligible employees pursuant to the NeurAxis, Inc. 2025 Employee Stock Purchase Plan effective as of July 1, 2025 and subject to shareholder approval by July 1, 2026. On April 9, 2026, the Company’s Board of Directors approved the cancelation of 1,319,394 stock options issued under the 2017 Innovative Health Solutions, Inc. 2017 Stock Compensation Plan and the grant of an equivalent amount of RSUs with immediate vesting under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, subject to shareholder approval. The stock option cancelation and RSU grant will be treated as a modification under ASC 718, Compensation—Stock Compensation , whereby the Company will recognize incremental compensation cost as the excess of the fair value of the granted RSUs over the fair value of the stock options immediately before the exchange. The Company estimates $ 4,250,000 of incremental compensation cost will be recorded upon approval of the exchange by the shareholders. On April 10, 2026, the Company’s Board of Directors declared a dividend on the Series B Preferred Stock. Holders of record of the Company’s Series B Preferred Stock as the record date of April 21, 2026, received a stock dividend on April 28, 2026, of the Company’s par value $ 0.001 Common Stock for every share of Series B Preferred Stock. The Company issued 510,605 shares of Common Stock based on the 8.5 % per annum cumulative dividend rate. On April 22, 2026, the Company granted 40,000 RSUs to an employee and issued 27,483 shares of common stock, net of taxes, upon vesting. On May 7, 2026, the Company issued 72,282 shares of common stock to an investor upon conversion of an equivalent amount of Series B Preferred Stock. In April and May of 2026, pursuant to the August 2025 At The Market Offering Agreement with Craig-Hallum Capital Group LLC, the Company issued 242,255 shares of common stock to investors for gross proceeds of $ 1,982,528 with such shares registered pursuant to the Company’s effective Registration Statement on Form S-3 (File No. 333-283798), previously filed with the Securities and Exchange Commission (“SEC”) on December 13, 2024, and declared effective on February 11, 2025, and the related prospectus supplements filed with the SEC on August 29, 2025, October 23, 2025, and April 21, 2026. In April and May of 2026, the Company issued 37,850 shares of common stock upon exercise of an equivalent amount of common stock warrants for gross proceeds of $ 90,083 . The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q and determined that there have been no other events that have occurred that would require adjustments to our disclosures in the condensed financial statements. 22